Today: 23 June 2026
Browse Category

NASDAQ:ONCI 4 May 2026

Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks issued $20 million in Series B preferred stock to acquire Neurobridge IP Holdings’ CNS drug-delivery and neurotherapeutic patents, closing the deal May 1. The company said the transaction lifts its stockholders’ equity above Nasdaq’s $2.5 million listing minimum. Lunai shares traded at $0.3246 Monday, leaving its market value at $7.6 million. The acquired assets consist solely of patents, with no cash paid.
4 May 2026
···

Stock Market Today

  • ACM Research (ACMR) Shares Drop 5.27% Amid Mixed Sector Performance
    June 22, 2026, 7:12 PM EDT. ACM Research, Inc. (ACMR) shares fell 5.27% to $24.37, underperforming the S&P 500's 1.13% decline in the latest session. Over the past month, ACMR's 5.73% gain lags behind the Computer and Technology sector's 7.36% rise but outpaces the S&P 500's 3.55%. The company is expected to report earnings per share (EPS) of $0.42, down 23.64% year-over-year, with revenue projected at $221.04 million, a 9.17% increase. Fiscal year estimates show EPS at $2.00, a decrease of 11.5%, and revenue up 16.64%. ACMR holds a Forward P/E of 12.86, in line with its industry average. The Semiconductor Equipment industry ranks in the bottom 5% of sectors, reflecting cautious investor sentiment. ACMR's Zacks Rank is #4 (Sell), indicating negative near-term outlook.

Latest articles

Nexentis Soars 156% on AI Drug Discovery Plans, Shares Fall After the Bell

Nexentis Soars 156% on AI Drug Discovery Plans, Shares Fall After the Bell

23 June 2026
Nexentis Technologies shares soared 155.91% to $13.00 on massive volume after announcing an AI drug-discovery partnership and a $2.9 million stock-and-warrant financing at $7.056 per share, but fell 26.15% after hours as investors weighed the promise of new research against dilution risk and a going-concern warning.
Grab Stock Falls Again as Traders Question Profitability

Grab Stock Falls Again as Traders Question Profitability

23 June 2026
Grab shares slid 2.24% to $3.49 despite first-quarter revenue jumping 24% and record adjusted EBITDA, as investors weighed a $500 million buyback and AI push against surging incentives and fuel costs; the stock is down 30% this year, trading near its 52-week low, with the market still skeptical about Grab’s profit turnaround.
Go toTop